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Background: It was proposed that glutathione S-transferase P1 (GSTP1) gene involved in detox-
ification of electrophilic substances may be related with lung function. The present study
aimed at investigating the correlation between GSTP1 105Val/Val genotype and chronic
obstruct pulmonary disease (COPD) using a meta-analysis of existed studies.
Methods: The Embase, Ovid, and PubMed databases were searched to identify eligible studies
published before October 1, 2009. Data were extracted using standardized forms and the
pooled odds ratios (ORs) with 95% confidence intervals (CI) were assessed by a model of fixed-
or random effects.
Results: The values of odds ratios(ORs) for COPD were 0.634 (95%CI 0.426e0.943, pZ 0.025) in
GSTP1 Ile/Ile, 0.625 (95%CI 0.418e0.935, p Z 0.022) in GSTP1 Ile/Val, and 0.633 (95% CI
0.430e0.933, pZ 0.021) in both, as compared to GSTP1 Val/Val, respectively. The individuals
with GSTP1 105Ile/Ile, Ile/Val, and both have about 37% reduction in the odds of COPD, as
compared to individuals with GSTP1 105Val/Val.
Conclusions: The GSTP1 105Val/Val genotype is suggested to be a genetic contributor to COPD
susceptibility, which should be furthermore clarified by studies with large sample sizes and
careful control for age, sex, ethnicity, and cigarette smoking.
ª 2010 Elsevier Ltd. All rights reserved.n (C. Chen), Xiangdong.wang@telia.com (X. Wang).
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by poorly reversible and progressive airflow limita-
tion and persistent airway inflammation1 and becomes the
fourth most common single cause of death.2 Of many COPD
risk factors, the genetic susceptibility may play an impor-
tant role in the development of COPD, since only small
population (25%) of continuous smokers developed symp-
tomatic COPD.3 It was hypothesized that the development
of COPD may be associated with the genetic variation in the
enzymes that detoxify cigarette smoke products, such as
glutathione S-transferases (GSTs). GSTs are a functionally
diverse family of enzymes involved in the conjugation of
a wide range of electrophilic substances with glutathione,
facilitating detoxification, metabolism and excretion of the
smoke products. Of the six classes of GSTs, i.e. alpha
(GSTA), mu (GSTM1), pi (GSTP1), theta (GSTT1), sigma and
kappa, GSTP1 was expressed more abundantly in respira-
tory tissue.4 Polymorphisms of GSTP1 genotypes include
isoleucine (Ile) 105 to valine (Val) mutation in exon 5 and
alanine 114 to Val mutation in exon 6. Though a number of
studies had been conducted to establish the links between
GSTP1 105Val/Val genotype and COPD risk in different
ethnic populations,5e16 most of the studies failed to find
a definite connection between them, probably due to small
sample sizes in those studies. The present study aimed at
investigating the correlation between GSTP1 105Val/Val
genotype and COPD using a meta-analysis of the available,
published, case-control or prospective longitudinal cohort
studies.
Methods
Search strategies
We searched Embase, Ovid, and PubMed to identify eligible
studies published before October 1, 2009, without lower
date limit. Although no language restrictions were imposed
initially, our resources only permitted review of literaturein English and Chinese. The search terms used were:
‘‘pulmonary disease, chronic obstructive’’, ‘‘chronic
obstructive lung disease’’, ‘‘chronic obstructive pulmonary
disease’’, ‘‘COPD’’, ‘‘glutathione S-Transferase pi’’ and
‘‘GSTP1’’. We also manually searched the references lists
of relevant publications.
Inclusion criteria and data extraction
Included studies had to meet the following criteria: 1)
studies with case-control or prospective longitudinal cohort
design, 2) COPD as the outcome, with at least two
comparison groups (COPD vs control groups), 3) determi-
nation of GSTP1 polymorphisms at exon 5, 4) provision of
the genotype frequency and 5) sufficient information for
extraction of data. Studies based on family or sibling pairs
were excluded. Two investigators (Drs Yan and Jin) inde-
pendently evaluated studies for inclusion, and disagree-
ments were resolved by discussions with the third person
(Dr. Shen). A standardized data extraction form used in the
present analyses included patient ethnicity, case sources,
control sources, COPD definition, ascertainment of
controls, HardyeWeinberg equilibrium testing, and adjust-
ment for smoking.
Evaluation of study quality
Study quality was assessed by ascertaining: 1) COPD was
diagnosed by spirometry, 2) controls were determined by
spirometry, 3) studies matched for cigarette smoking, and
4) HardyeWeinberg equilibrium was tested. The studies
were sub-grouped in terms of the study quality and each
subgroup was separately subjected to meta-analysis.
Statistical analysis
Statistical analyses were performed using STATA release 8.2
(STATA Corp, College Station, TX, USA). GSTP1 105Ile/Ile
and 105Val/Val were highly focused in the present analysis,
on basis of the previous findings that both genotypes were
Table 1 Summary of 10 publications included in meta-analyses of glutathione S-transferase P1 (GSTP1) polymorphism and chronic obstructive pulmonary disease (COPD)
susceptibility.
Reference Ethnicity Source of cases Source of controls COPD definition Ascertainment
of controls
HWE Adjustment
for smoking
Rodriguez6 Caucasian Hospitalclinics Subjects who were
admitted for a checkup
Spanish Society of Pneumology and Thoracic
Surgery criteria
Not described Yes No
Xiao7 Asia Hospital patients Healthy controls The guideline of diagnosis and management
for COPD(China, 2002)
Objective test
(spirometry)
Yes Yes
Gaspa8 Caucasian Hospital patients Subjects who were
admitted for paternity tests
The guidelines of the European
Respiratory Society (1995)
No Objective
testing
Yes No
Cheng9 Asia Hospital patients Health checkup
individual
American Thoracic
Society guidelines
Objective test
(spirometry)
Yes Yes
Vibhuti10 Asia Hospital patients Healthy controls ATS criteria Objective test
(spirometry)
Yes Yes
Yim11 Asia Hospital patients Subjects who were
admitted for a checkup
Symptoms FEV1<80%
predicted FEV1/FVC<70%
Objective test
(spirometry)
Yes No
LU12 Asia Hospital patients Healthy controls The guideline of diagnosis and management
for COPD(China, 1997)
Objective test
(spirometry)
Yes Yes
Yeung13 Asia Hospital patients Healthy controls GOLD criteria Objective test
(spirometry)
Yes Yes
Ishii14 Asia Hospital patients Healthy controls The guideline of the European
Respiratory Society
Not described Yes Yes
Harries15 Caucasian Hospital patients Healthy controls Clinical diagnosis Not described No No
HWE: HardyeWeinberg equilibrium; FEV1: Forced Expiratory Volume in 1 Second; FVC: forced vital capacity.
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Table 2 Genotype and allele frequencies of glutathione S-transferase P1 (GSTP1) in all included studies with chronic
obstructive pulmonary disease (COPD) and control groups.
Reference COPD group Control group
Genotype (n) Allele (%) Genotype (n) Allele (%)
105Ile/Ile 105Ile/Val 105Val/Val Ile 105Ile/Ile 105Ile/Val 105Val/Val Ile
Rodriguez6 52 36 10 71.4 97 88 13 71.2
Xiao7 57 40 3 77 70 29 1 84.5
Gaspa8 35 35 5 70 47 36 7 72.2
Cheng9 97 78 9 74 99 98 15 64
Vibhuti10 105 75 22 70.5 90 42 4 81.6
Yim11 63 24 2 84.3 57 35 2 79.3
LU12 70 22 5 84 41 24 2 79
Yeung13 112 43 8 81.9 112 47 2 84.2
Ish105Ile/Ile14 42 11 0 90 26 22 2 74
Harries15 34 35 10 65.2 79 66 10 72.3
476 F. Yan et al.suggested to be associated with COPD susceptibility and
COPD severity, respective.14,17,18 The odds ratios of COPD
were recalculated and compared between 105Ile/Ile and
105Val/Val, 105Ile/Ile and 105Ile/Val, 105Ile/Ile and
105Ile/Valþ105Val/Val, 105Ile/Val and 105Val/Val, and
105Ile/Ileþ105Ile/Val and 105Val/Val. The corresponding
95% confidence intervals (CI) were estimated by Woolf’s
method.19 X2 test was used for evaluating the Hardye
Weinberg equilibrium in each study. Publication bias was
assessed using funnel plots Begg test and Egger test.20,21 If
no publication bias existed, the funnel plot was considered
as symmetrical.22 Heterogeneity among studies was exam-
ined with Q and I2 statistics.23 P values less than 0.05 were
considered significant in the Q statistics, suggesting that
there was heterogeneity across studies. I2 was interpreted
as the proportion of variation in the log odds ratios attrib-
utable to genuine differences across studies rather than toFigure 1 Values of odds ratios for chronic obstructive pulmonary
Val allele. The center of a box and the horizontal line represent th
with the size of the boxes representing the weight.random error.24 If heterogeneity across studies existed,
a sensitive analysis was performed based on the magnitude
of the Q statistic.25 If no heterogeneity was found among
studies, a fixed effect model was used to determine the
gene effect26 or the random effect model was used.27 The
analyses were also performed between the subgroups of
studies controlled for smoking and ethnicity.Results
Search results and study quality
We identified 12 publications evaluating an association
between GSTP1 105Val/Val genotype and COPD. Two were
subsequently excluded, one because that two reports
included the same patients,7,16 where only that with thedisease when the GSTP1 Ile allele was compared to the GSTP1
e odds ratios and the 95% confidential index (CI), respectively,
Figure 2 Values of odds ratios for chronic obstructive
pulmonary disease when the GSTP1 105Val/Val genotype was
compared to GSTP1 105Ile/Ile genotype (A) or the GSTP1 Ile/
Val genotype (B), and the GSTP1 Ile/Ile and Ile/Val genotypes
(C).
Figure 3 Begg’s funnel plots for publication bias analysis of
studies comparing between GSTP1 105Ile/Ile and GSTP1
105Val/Val (A), GSTP1 105Ile/Val and GSTP1 105Val/Val (B),
and GSTP1 105Ile/Ileþ105Ile/Val and 105Val/Val (C),
respectively.
Association between polymorphism of GSTP1 and COPD 477better quality study was included, and the another because
that the total number of patients did not equal to the sum
of the patients in all subgroups and the controls were in
HardyeWeinberg disequilibrium. Therefore, there were teneligible studies6e15 in total 1140 cases and 1263 controls
(Table 1). Seven studies were involved in Asian subjects,
while three in Caucasian subjects. All studies used PCR-
based methods for genotyping. The distribution of geno-
types and allele frequencies of GSTP1 in patients and
controls are presented in Table 2. Quality assessment of
studies is shown in Table 1, of which nine was defined as
COPD by spirometry criteria. Controls in six studies7,9e13
were assessed using objectives criteria, including spirom-
etry and six studies7,9,10,12e14 included cigarette smoking.
Table 3 Pooled odds ratios for COPD susceptibility in meta-analysis: comparisons of alleles and genotypes.
Comparison Na Odds ratios (95% CI) p values Publication biasb Heterogeneity testb
Egger Begg p I2 c2
Ile vs Val 10 0.972 (0.755e1.252) 0.828d p > 0.1 p > 0.1 0.001 0.685 28.6
105Ile/Ile vs 105Val/Val 9 0.634 (0.426e0.943) 0.025c p > 0.1 p > 0.1 0.161 0.321 11.78
105Ile/Val vs 105Val/Val 9 0.625 (0.418e0.935) 0.022c p > 0.1 p > 0.1 0.453 0 7.81
105Ile/Ileþ105Ile/Val vs 105Val/Val 9 0.633 (0.430e0.933) 0.021c p > 0.1 p > 0.1 0.263 0.202 10.03
105Ile/Ile vs 105Ile/Val 10 1.095 (0.831e1.443) 0.519d p > 0.1 p > 0.1 0.011 0.577 21.29
105Ile/Ile vs 105Ile/Valþ105Val/Val 10 1.037 (0.772e1.393) 0.809d p > 0.05 p > 0.1 0.002 0.658 26.35
I2 is interpreted as the proportion of total variation caused by between-study variation.
a The number of studies included.
b p < 0.05 is considered statistically significant.
c Fixed effects models were used.
d Random effects models were used.
478 F. Yan et al.Results from recalculation with HardyeWeinberg equilib-
rium showed that the distribution of GSTP1 genotypes
within cases and controls was consistent.
Association between GSTP1 105Ile/val allele
and COPD
No significant association between GSTP1 105Ile/Val allele
and COPD was found. Under an additive genetic model, the
summary OR of COPD by random effects was 0.972 (95% CI
0.755e1.252, p Z 0.828) for individuals with the 105Ile
allele, as compared to those with the 105Val allele (Fig. 1).
Significant heterogeneity was detected among the studies
(Q test: X2 Z 25.2, p Z 0.003, I2 Z 64.2%). Analysis of
subgroups controlled for cigarette smoking and ethnicity
revealed no significant difference in the pooled OR values
for COPD among these subgroups (data not shown).
Association between GSTP1 genotypes and COPD
Only one study14 showed that the GSTP1 105Ile/Ile geno-
type was associated with COPD, where the OR for COPD was
3.5 (95% CI 2.7e4.6), as compared to other genotypes. In
the present analyses under a genotype-based model, the
summary ORs for COPD with 105Val/Val individuals were
0.634 (95% CI 0.426 to 0.943, p Z 0.025), 0.625 (95% CI
0.418 to 0.935, pZ 0.022) and 0.633(95% CI 0.430 to 0.933,
pZ 0.021), as compared to 105Ile/Ile (Fig. 2 A), 105Ile/Val
(Fig. 2B), and 105Ile/Ileþ105Ile/Val (Fig. 2C), respectively.
No significant heterogeneity was found in these studies.
The pooled results showed that the odds of COPD with
105Ile/Ile, 105Ile/Val, and 105Ile/Ileþ105Ile/Val were
about 37%, respectively, less than those with 105Val/Val
alone. There was no statistical significance between control
groups for cigarette smoking and ethnicity, between
105Ile/Ile and 105Ile/Val genotypes, and between 105Ile/
Ile and 105Ile/Val þ 105Val/Val genotypes. However, there
was a significant heterogeneity among those (Q test,
105Ile/Ile vs 105Ile/Val: X2 Z 21.29 p Z 0.01 I2 Z 57.7%;
105Ile/Ile vs 105Ile/Valþ105Val/Val: X2 Z 26.35 p Z 0.002
I2 Z 65.8%). The funnel plots were symmetrical and the
Begg test and Egger test did not show significant among all
studies, shown in Fig. 3. The results of the pooled analysis
for the studies are presented in Table 3.Discussion
The results from the present analyses indicate that the
GSTP1 105Val/Val genotype genetically contributes to the
susceptibility to COPD. GSTP1 is well known to play an
important role in the protection from lung injury by
detoxifying the harmful components of tobacco smoke.
While, the GSTP1 105Val/Val genotype was found to be less
active in detoxification than the 105Ile/Ile genotype,
leading to an extended exposure to cigarette smoke and
more severe destruction and inflammation of lung paren-
chyma.9 We performed a meta-analysis of the available
studies on GSTP1 polymorphism and COPD risk and found
a significant association between the GSTP1 105Val/Val and
COPD. This is different from the findings that the GSTP1
105Ile/Ile genotype was a significant risk for COPD and the
homozygous 105Ile genotype might be less effective in
protecting an individual against xenobiotics from tobacco
smoke.14 It may be due to the fact that there was a small
sample size in that particular study and the 105Ile allelic
frequency observed was lower than that reported in two
previous studies in Japanese healthy volunteers.28,29
Another reason may be that the effect of GSTP1 105Val/Val
genotype on detoxification is controversial. Some in vitro
studies demonstrated that GSTP1 105Val was more active in
detoxification than GSTP1 105Ile,30,31 while others sug-
gested that the 105Val mutation reduce enzyme activity
and 1-chloro-2.4 dinitrobenzene conjugation activity of
GSTP1 105Val in the human lung tissue.32,33
Our findings on the correlation between GSTP1 105Val/
Val and COPD are indirectly supported by the evidence that
GSTP1 105Val/Val was found to be associated with a fast
lung function decline in 1098 patients with different
degrees of lung function impairment.17 Indirect evidence is
that annual rates of increase in forced expiratory volume in
1 s and forced vital capacity reduced in children homozy-
gous for the 105Val variant.18 The results from the present
analyses failed to reveal the significant association
between the GSTP1 105Ile/Val allele and COPD. However, it
could not rule out the possibility that such failure might
result from the lower statistical power. On the other hand,
it should be ware of the potential of false positive associ-
ation, since the most studies with positive correlation could
be published. It is important to perform big genome wide
Association between polymorphism of GSTP1 and COPD 479association studies with hypothesis-free approach,
combining several large longitudinal cohort studies
involving more than 10.000 participants, correcting strictly
for multiple testing and replicating the findings in other
independent cohorts.
The present analyses were influenced by the quality of
the original studies. For example, the cigarette smoking in
the industrial countries is the major environmental risk
factor for COPD, while some of the included studies did not
adjust for smoking as a potential confounder. Other
important potential confounders, such as age and sex, were
not adjusted in some studies either. Lack of adjustment for
confounders is a likely source of heterogeneity between
studies. In addition, some studies recruited cases and
control subjects from hospitals, which may cause selection
bias. Another limitation to be considered is the studies in
the present analyses were restricted to English and Chinese
language publications.
In conclusion, the results from the present analyses
showed a correlation between GSTP1 105Val/Val and COPD,
indicating that the GSTP1 105Val/Val genotype may be
a risk factor in the pathogenesis of COPD. There is the great
need of further studies involving large populations and
careful control with age, sex, ethnicity, and cigarette
smoking, to confirm the role of GSTP1 105Val/Val in the
development of COPD.
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